Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that it
plans to report its fiscal second quarter and six months ended financial
results before the U.S. markets open on May 12, 2014. Enanta management
will host a conference call at 8:30 a.m. ET to discuss these results and
to provide an update on its research and development pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855) 840-0595
in the U.S. or (518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 11:30 a.m.
Eastern time on May 12, 2014, through 11:59 p.m. Eastern time on May 16,
2014 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for
international callers. The passcode for both the live call and the
replay is 31914722. A live audio webcast of the call and replay will be
accessible on our website at www.enanta.com
for no more than 30 days. Please visit the Investor home page of our
website and search for calendar of events. A replay of the webcast will
be available on www.enanta.com
approximately two hours following the live webcast.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases,
developing novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of three direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase – as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Copyright Business Wire 2014